{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T05:10:34Z","timestamp":1792905034006,"version":"4.5.0"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100002636","name":"Inje University","doi-asserted-by":"publisher","award":["20230003"],"award-info":[{"award-number":["20230003"]}],"id":[{"id":"10.13039\/501100002636","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Team Science Award"},{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2022-0150"],"award-info":[{"award-number":["6-2022-0150"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Dopamine agonist (DA) treatment is effective for hyperprolactinemia and reduces tumor size in patients with prolactinoma; however, prolonged DA administration without prolactinoma causes fibrosis around tumor tissues. Therefore, we aimed to identify circulating microRNAs (miRNAs) as potential biomarkers to predict prolactinoma in patients with hyperprolactinemia and pituitary tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Plasma samples were collected from 3 comparison groups: (1) patients clinically diagnosed with prolactinoma vs nonfunctioning pituitary adenoma (NFPA) based on response to cabergoline treatment, (2) patients with surgically confirmed prolactinoma vs NFPA, and (3) patients before and after cabergoline treatment. Candidate miRNAs from the initial nCounter assay were validated using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) in a larger cohort of 247 patients with hyperprolactinemia and 37 controls.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The nCounter assay was used for miRNA expression profiling, and the qRT-PCR validated the candidate miRNAs in the plasma and tumor tissue samples. Total RNA sequencing was conducted on pituitary tumor tissues to identify transcriptomic alterations. Furthermore, candidate miRNA target genes and their biological roles were analyzed using prolactinoma cell lines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Three miRNA candidates (miR-20a-5p, miR-424-5p, and miR-514a-5p) were selected by analyzing 3 sets of expression comparisons between the 2 groups. Furthermore, the relative miR-20a-5p expression significantly increased in prolactinoma compared with that in normal pituitary glands, NFPA, growth hormone-secreting pituitary adenoma, and adrenocorticotropic hormone-secreting pituitary adenoma. In MMQ and GH4 cells, miR-20a-5p inhibition decreased prolactinoma cell proliferation and prolactin secretion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Circulating miR-20a-5p is a potential biomarker for prolactinoma, which could be associated with responsiveness to DAs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf025","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T18:18:21Z","timestamp":1743272301000},"page":"335-345","source":"Crossref","is-referenced-by-count":5,"title":["Circulating miR-20a-5p as a biomarker associated with cabergoline responsiveness in patients with hyperprolactinemia and pituitary adenomas"],"prefix":"10.1093","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4620-5621","authenticated-orcid":false,"given":"Yang Jong","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Endocrinology, Institute of Endocrine Research, Yonsei University College of Medicine , Seoul 03722 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Won","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine , Goyang 10380 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjae","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Yonsei University College of Medicine , Seoul 03722 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisup","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Endocrinology, Institute of Endocrine Research, Yonsei University College of Medicine , Seoul 03722 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5822-5235","authenticated-orcid":false,"given":"Chan Woo","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Endocrinology, Institute of Endocrine Research, Yonsei University College of Medicine , Seoul 03722 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Ho","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Medicine and Health Sciences , New York, NY 10012 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hyung","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Yonsei University College of Medicine , Seoul 03722 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Yonsei University College of Medicine , Seoul 03722 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8693-9630","authenticated-orcid":false,"given":"Cheol Ryong","family":"Ku","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Endocrinology, Institute of Endocrine Research, Yonsei University College of Medicine , Seoul 03722 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9876-8370","authenticated-orcid":false,"given":"Eun Jig","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Endocrinology, Institute of Endocrine Research, Yonsei University College of Medicine , Seoul 03722 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"7","key":"2025040203000937400_lvaf025-B1","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3275\/8815","article-title":"Serum prolactin concentration at presentation of non-functioning pituitary macroadenomas","volume":"36","author":"Behan","year":"2013","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2025040203000937400_lvaf025-B2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2265.2006.02627.x","article-title":"Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma","volume":"65","author":"Karavitaki","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2025040203000937400_lvaf025-B3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s12020-009-9279-7","article-title":"Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma","volume":"37","author":"Hong","year":"2010","journal-title":"Endocrine"},{"issue":"2","key":"2025040203000937400_lvaf025-B4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3171\/2019.3.JNS19121","article-title":"Prolactinomas and nonfunctioning adenomas: preoperative diagnosis of tumor type using serum prolactin and tumor size","volume":"133","author":"Burke","year":"2019","journal-title":"J Neurosurg"},{"issue":"6463","key":"2025040203000937400_lvaf025-B5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/bmj.290.6463.182","article-title":"Prolactinomas","volume":"290","author":"Grossman","year":"1985","journal-title":"Br Med J"},{"issue":"5","key":"2025040203000937400_lvaf025-B6","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1210\/jcem.85.5.6611","article-title":"The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas","volume":"85","author":"Arafah","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025040203000937400_lvaf025-B7","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1530\/eje.1.02298","article-title":"Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors","volume":"155","author":"Ferrante","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2025040203000937400_lvaf025-B8","doi-asserted-by":"publisher","first-page":"E527","DOI":"10.1227\/NEU.0000000000001387","article-title":"Congress of neurological surgeons systematic review and evidence-based guideline for pretreatment endocrine evaluation of patients with nonfunctioning pituitary adenomas","volume":"79","author":"Fleseriu","year":"2016","journal-title":"Neurosurgery"},{"issue":"6","key":"2025040203000937400_lvaf025-B9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3803\/EnM.2023.1838","article-title":"Update on current evidence for the diagnosis and management of nonfunctioning pituitary neuroendocrine tumors","volume":"38","author":"Whyte","year":"2023","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"21","key":"2025040203000937400_lvaf025-B10","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1056\/NEJMcp025334","article-title":"Clinical practice. Prolactinoma","volume":"349","author":"Schlechte","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"2025040203000937400_lvaf025-B11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025040203000937400_lvaf025-B12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"issue":"4","key":"2025040203000937400_lvaf025-B13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1677\/ERC-08-0181","article-title":"Medical therapy for clinically non-functioning pituitary adenomas","volume":"15","author":"Colao","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2025040203000937400_lvaf025-B14","doi-asserted-by":"publisher","first-page":"E533","DOI":"10.1227\/NEU.0000000000001389","article-title":"Congress of neurological surgeons systematic review and evidence-based guideline on primary management of patients with nonfunctioning pituitary adenomas","volume":"79","author":"Lucas","year":"2016","journal-title":"Neurosurgery"},{"issue":"4","key":"2025040203000937400_lvaf025-B15","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1210\/jc.2003-030859","article-title":"Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment","volume":"89","author":"Pivonello","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025040203000937400_lvaf025-B16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1023\/A:1015366923810","article-title":"Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline","volume":"4","author":"Lohmann","year":"2001","journal-title":"Pituitary"},{"issue":"1","key":"2025040203000937400_lvaf025-B17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11102-010-0261-4","article-title":"Effect of dopaminergic drug treatment on surgical findings in prolactinomas","volume":"14","author":"Menucci","year":"2011","journal-title":"Pituitary"},{"issue":"2","key":"2025040203000937400_lvaf025-B18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1210\/jcem-63-2-383","article-title":"Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland","volume":"63","author":"Esiri","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"2025040203000937400_lvaf025-B19","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-220971","article-title":"Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective","volume":"2017","author":"Mohan","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"2","key":"2025040203000937400_lvaf025-B20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"issue":"6","key":"2025040203000937400_lvaf025-B21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3803\/EnM.2022.1565","article-title":"Inhibition of miR-146a-5p and miR-8114 in insulin-secreting cells contributes to the protection of melatonin against stearic acid-induced cellular senescence by targeting MAFA","volume":"37","author":"Su","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2025040203000937400_lvaf025-B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-94-007-5590-1_1","article-title":"MicroRNAs in human cancer","volume":"774","author":"Farazi","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"2025040203000937400_lvaf025-B23","doi-asserted-by":"publisher","first-page":"435171","DOI":"10.1155\/2014\/435171","article-title":"MicroRNAs in human pituitary adenomas","volume":"2014","author":"Li","year":"2014","journal-title":"Int J Endocrinol"},{"issue":"10","key":"2025040203000937400_lvaf025-B24","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/BF03346759","article-title":"MicroRNAs: suggested role in pituitary adenoma pathogenesis","volume":"36","author":"Gadelha","year":"2013","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2025040203000937400_lvaf025-B25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1227\/NEU.0000000000000369","article-title":"MicroRNAs as biomarkers in pituitary tumors","volume":"75","author":"Di Ieva","year":"2014","journal-title":"Neurosurgery"},{"issue":"6","key":"2025040203000937400_lvaf025-B26","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3892\/ijo.2012.1647","article-title":"Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review)","volume":"41","author":"Allegra","year":"2012","journal-title":"Int J Oncol"},{"issue":"7","key":"2025040203000937400_lvaf025-B27","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1515\/cclm-2018-0838","article-title":"The circulating miRNAs as diagnostic and prognostic markers","volume":"57","author":"Terrinoni","year":"2019","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"2025040203000937400_lvaf025-B28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/modpathol.2008.202","article-title":"Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas","volume":"22","author":"Qian","year":"2009","journal-title":"Mod Pathol"},{"issue":"1-2","key":"2025040203000937400_lvaf025-B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2014.03.002","article-title":"Mir-23b and miR-130b expression is downregulated in pituitary adenomas","volume":"390","author":"Leone","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"13","key":"2025040203000937400_lvaf025-B30","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/onc.2012.190","article-title":"Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation the PTEN-AKT pathway","volume":"32","author":"Palumbo","year":"2013","journal-title":"Oncogene"},{"issue":"9","key":"2025040203000937400_lvaf025-B31","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1210\/jc.2018-02479","article-title":"Comprehensive analysis of circulating microRNAs in plasma of patients with pituitary adenomas","volume":"104","author":"N\u00e9meth","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025040203000937400_lvaf025-B32","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12957-021-02383-3","article-title":"Potential biomarkers of miRNA in non-functional pituitary adenomas","volume":"19","author":"Zhang","year":"2021","journal-title":"World J Surg Oncol"},{"issue":"3","key":"2025040203000937400_lvaf025-B33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ncrna.2021.06.004","article-title":"Differential non-coding RNAs expression profiles of invasive and non-invasive pituitary adenomas","volume":"6","author":"Beylerli","year":"2021","journal-title":"Noncoding RNA Res"},{"issue":"12","key":"2025040203000937400_lvaf025-B34","first-page":"882","article-title":"Reduced accumulation of specific microRNAs in colorectal neoplasia","volume":"1","author":"Michael","year":"2003","journal-title":"Mol Cancer Res"},{"issue":"8","key":"2025040203000937400_lvaf025-B35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1160\/TH16-01-0071","article-title":"Diagnostic potential of plasma microRNA signatures in patients with deep-vein thrombosis","volume":"116","author":"Wang","year":"2016","journal-title":"Thromb Haemost"},{"issue":"29","key":"2025040203000937400_lvaf025-B36","doi-asserted-by":"publisher","first-page":"45199","DOI":"10.18632\/oncotarget.9900","article-title":"MicroRNA-20a-5p promotes colorectal cancer invasion and metastasis by downregulating Smad4","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"2025040203000937400_lvaf025-B37","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.3892\/or.2016.5144","article-title":"MicroRNA-20a-5p targets RUNX3 to regulate proliferation and migration of human hepatocellular cancer cells","volume":"36","author":"Chen","year":"2016","journal-title":"Oncol Rep"},{"issue":"12","key":"2025040203000937400_lvaf025-B38","first-page":"5715","article-title":"MicroRNA-20a-5p inhibits epithelial to mesenchymal transition and invasion of endometrial cancer cells by targeting STAT3","volume":"11","author":"Huang","year":"2018","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"2025040203000937400_lvaf025-B39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12935-017-0499-2","article-title":"MiR-20a-5p suppresses tumor proliferation by targeting autophagy-related gene 7 in neuroblastoma","volume":"18","author":"Yu","year":"2018","journal-title":"Cancer Cell Int"},{"issue":"6","key":"2025040203000937400_lvaf025-B40","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/jog.13317","article-title":"Plasma microRNA-16-5p, \u221217\u20135p and \u221220a-5p: novel diagnostic biomarkers for gestational diabetes mellitus","volume":"43","author":"Cao","year":"2017","journal-title":"J Obstet Gynaecol Res"},{"issue":"3","key":"2025040203000937400_lvaf025-B41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40291-018-0325-0","article-title":"Decreased expression of circulating miR-20a-5p in South African women with gestational diabetes Mellitus","volume":"22","author":"Pheiffer","year":"2018","journal-title":"Mol Diagn Ther"},{"issue":"20","key":"2025040203000937400_lvaf025-B42","doi-asserted-by":"publisher","first-page":"12253","DOI":"10.3390\/ijms232012253","article-title":"Association between circulating microRNAs (miR-21-5p, miR-20a\u20135p, miR-29b-3p, miR-126-3p and miR-101-3p) and chronic allograft dysfunction in renal transplant recipients","volume":"23","author":"Chen","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025040203000937400_lvaf025-B43","first-page":"1057","article-title":"Evaluation of circulating miRNAs in wet age-related macular degeneration","volume":"20","author":"Ertekin","year":"2014","journal-title":"Mol Vis"},{"issue":"5","key":"2025040203000937400_lvaf025-B44","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3892\/or.2012.1690","article-title":"microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment","volume":"27","author":"Wang","year":"2012","journal-title":"Oncol Rep"},{"issue":"1-2","key":"2025040203000937400_lvaf025-B45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.mce.2014.07.014","article-title":"MicroRNA expression profile of bromocriptine-resistant prolactinomas","volume":"395","author":"Wu","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"2025040203000937400_lvaf025-B46","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40618-018-0963-4","article-title":"Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1","volume":"42","author":"Jian","year":"2019","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2025040203000937400_lvaf025-B47","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.gpb.2018.03.004","article-title":"Identification and analysis of human sex-biased microRNAs","volume":"16","author":"Cui","year":"2018","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"4","key":"2025040203000937400_lvaf025-B48","doi-asserted-by":"publisher","first-page":"692","DOI":"10.4161\/rna.8.4.16029","article-title":"Population differences in microRNA expression and biological implications","volume":"8","author":"Huang","year":"2011","journal-title":"RNA Biol"},{"issue":"5","key":"2025040203000937400_lvaf025-B49","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1373\/clinchem.2012.195776","article-title":"Targeting the circulating microRNA signature of obesity","volume":"59","author":"Ortega","year":"2013","journal-title":"Clin Chem"},{"issue":"1","key":"2025040203000937400_lvaf025-B50","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12935-017-0470-2","article-title":"MiR-20a-5p represses the multi-drug resistance of osteosarcoma by targeting the SDC2 gene","volume":"17","author":"Zhao","year":"2017","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2025040203000937400_lvaf025-B51","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-016-0340-3","article-title":"MiR-20a-5p represses multi-drug resistance in osteosarcoma by targeting the KIF26B gene","volume":"16","author":"Pu","year":"2016","journal-title":"Cancer Cell Int"},{"issue":"5","key":"2025040203000937400_lvaf025-B52","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20181374","article-title":"MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy","volume":"39","author":"Lu","year":"2019","journal-title":"Biosci Rep"},{"issue":"3","key":"2025040203000937400_lvaf025-B53","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1161\/CIRCRESAHA.111.247452","article-title":"Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?","volume":"110","author":"Creemers","year":"2012","journal-title":"Circ Res"},{"issue":"16","key":"2025040203000937400_lvaf025-B54","doi-asserted-by":"publisher","first-page":"7223","DOI":"10.1093\/nar\/gkr254","article-title":"Characterization of extracellular circulating microRNA","volume":"39","author":"Turchinovich","year":"2011","journal-title":"Nucleic Acids Res"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/192\/4\/335\/62834804\/lvaf025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/192\/4\/335\/62834804\/lvaf025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T03:01:19Z","timestamp":1743562879000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/192\/4\/335\/8102968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf025","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,27]]}}}